Abvc Biopharma (ABVC) Non-Current Receivables (2021 - 2024)
Historic Non-Current Receivables for Abvc Biopharma (ABVC) over the last 4 years, with Q3 2024 value amounting to $124151.0.
- Abvc Biopharma's Non-Current Receivables fell 8665.61% to $124151.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $124151.0, marking a year-over-year decrease of 8665.61%. This contributed to the annual value of $113516.0 for FY2023, which is 8688.4% down from last year.
- Per Abvc Biopharma's latest filing, its Non-Current Receivables stood at $124151.0 for Q3 2024, which was down 8665.61% from $121392.0 recorded in Q2 2024.
- Abvc Biopharma's 5-year Non-Current Receivables high stood at $1.2 million for Q3 2022, and its period low was $113516.0 during Q4 2023.
- Its 4-year average for Non-Current Receivables is $535841.6, with a median of $471167.0 in 2021.
- Its Non-Current Receivables has fluctuated over the past 5 years, first soared by 578.04% in 2022, then plummeted by 8688.4% in 2023.
- Quarter analysis of 4 years shows Abvc Biopharma's Non-Current Receivables stood at $818183.0 in 2021, then rose by 5.78% to $865477.0 in 2022, then plummeted by 86.88% to $113516.0 in 2023, then grew by 9.37% to $124151.0 in 2024.
- Its Non-Current Receivables stands at $124151.0 for Q3 2024, versus $121392.0 for Q2 2024 and $123363.0 for Q1 2024.